MAPS Public Benefit Corporation (MPBC) manages Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored psychedelic and marijuana research initiatives. MPBC’s primary work is to supervise the clinical trials in safety and efficacy required to apply for FDA approval of MDMA-assisted psychotherapy as a treatment for chronic, treatment-resistant posttraumatic stress disorder (PTSD). MPBC currently oversees US-based PTSD studies in Charleston, SC and Boulder, CO as well as international PTSD studies in Israel and Canada. MPBC is also exploring MDMA-assisted psychotherapy as a safe and effective treatment for social anxiety in autistic adults and anxiety associated with life-threatening illness.
 
On December 17, 2014 MAPS received a $2 million dollar grant from the state of Colorado to investigate the effects of smoked, whole-plant marijuana on PTSD symptoms in veterans. MPBC has been coordinating the development of this multi-site study and is currently waiting on delivery of marijuana from NIDA and the cooperation of out-of-state institutional review boards to proceed with the research.
 
MPBC’s additional on-going research projects include an examination of LSD-assisted psychotherapy as a treatment for anxiety associated with life-threating illness and observational studies of ayahuasca and ibogaine therapy for overcoming drug addiction.
 
To donate these studies please visit MAPS.org